Venom Hyperdrive is sold as a dietary supplement, which, according to the FDA, contains a controlled substance with risks for abuse or addiction, and is a potent drug that poses potential safety risks.
“Sibutramine is the active ingredient in an FDA-approved prescription drug used as an appetite suppressant for weight loss,” said Janet Woodcock MD, director of the FDA’s Center for Drug Evaluation and Research.
“When present in a dietary supplement, it may harm unsuspecting consumers, because sibutramine can substantially increase blood pressure and heart rate (pulse), and may present a significant risk for people with a history of heart disease, heart failure, irregular heart beats or stroke.”
Venom Hyperdrive 3.0 is marketed by Applied Lifescience Research Industries Inc of California. The company initiated a product recall of all lots of Venom Hyperdrive 3.0 after the FDA laboratory analysis showed samples of the product contained undeclared sibutramine.
Although ALR Industries claims on its website that only “trace amounts” of sibutramine were found in this product, the FDA laboratory tests showed that Venom Hyperdrive 3.0 contains a significant amount of sibutramine per dosage unit.
The product was sold via distributors and in retail stores nationwide, as well as in Canada, Poland, Sweden, Hungary, South Africa, the Netherlands, Australia, France and the UK. The company has reformulated and launched a new version called Venom Hyperdrive 3.0+, which hasn’t been affected by the FDA’s warning.
Source: The US Food and Drug Administration
© FoodBev Media Ltd 2024